Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00280-024-04657-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[This corrects the article DOI: 10.1002/jha2.885.
View Article and Find Full Text PDFCorrection to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
Cancer Chemother Pharmacol
September 2024
Novartis Pharma AG, 4002, Basel, Switzerland.
Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA).
BMC Cancer
July 2021
Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Background: Despite the introduction of targeted therapies, most patients with myeloid malignancies will not be cured and progress. Genomics is useful to elucidate the mutational landscape but remains limited in the prediction of therapeutic outcome and identification of targets for resistance. Dysregulation of phosphorylation-based signaling pathways is a hallmark of cancer, and therefore, kinase-inhibitors are playing an increasingly important role as targeted treatments.
View Article and Find Full Text PDFImproving awareness of several combination therapies for acute myeloid leukemia among oncology and hematology team members in Colorado, USA.
Hematol Transfus Cell Ther
February 2021
Complex Mechanisms of Disease, Aging and Trauma (CMDAT) Research Foundation, Denver, CO, United States.
Introduction: Although several combination therapies for acute myeloid leukemia (AML) have emerged recently, there has been a lack of published surveys and educational projects focused on these important treatment options. We aimed to improve the oncology team members' knowledge and awareness of several FDA approved combination therapies for AML, including glasdegib (DAURISMO®), venetoclax (VENCLEXTA®), GO (MYOLOTARG®),CPX-351 (VYXEOS®), and midostaurin (RYDAPT®). Additionally, we aimed to examine these teams' perspectives, views, and attitudes towards these topics and finally identify barriers to the implementationof such therapies in clinical practice.
View Article and Find Full Text PDFEquilibrium gel filtration to measure plasma protein binding of very highly bound drugs.
J Pharm Sci
February 2014
Novartis Institutes for Bio Medical Research, Basel, Switzerland.
For very highly bound drugs (fu < 2%), the determination of the unbound fraction in plasma (fu) and a reliable estimation of protein-binding differences across species, populations, or concentrations is challenging. The difficulty is not mostly assay sensitivity but rather experimental bias. In equilibrium gel filtration (EGF)--opposite to the commonly used methods--the amount bound at a set-free concentration is determined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!